Table 4.
Regression Model | No. of Patients | Overall Mortality | Failure for PFS | Relapse | NRM | ||||
---|---|---|---|---|---|---|---|---|---|
HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | ||
Disease status | |||||||||
MRD-negative remission | 235 | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | ||||
MRD-positive remission | 76 | 3.69 (2.51 to 5.42) | < .001 | 4.38 (3.04 to 6.33) | < .001 | 4.17 (2.69 to 6.47) | < .001 | 1.72 (0.93 to 3.18) | .083 |
Active disease | 48 | 4.40 (2.56 to 7.55) | < .001 | 5.30 (3.18 to 8.81) | < .001 | 4.87 (2.50 to 9.72) | < .001 | 1.37 (0.52 to 3.65) | .530 |
Age (per 10 years) | 1.12 (0.98 to 1.29) | .089 | 0.98 (0.87 to 1.10) | .704 | 0.87 (0.75 to 1.00) | .050 | 1.27 (0.99 to 1.65) | .065 | |
Cytogenetic risk group | |||||||||
Intermediate/favorable | 264 | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | ||||
Adverse | 89 | 0.90 (0.61 to 1.32) | .583 | 1.00 (0.70 to 1.45) | .979 | 1.19 (0.77 to 1.86) | .430 | 0.66 (0.34 to 1.32) | .240 |
Type of AML | |||||||||
De novo | 144 | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | ||||
Secondary | 97 | 1.01 (0.73 to 1.41) | .953 | 0.99 (0.72 to 1.35) | .945 | 0.91 (0.62 to 1.35) | .640 | 1.03 (0.55 to 1.93) | .880 |
Pre-HCT karyotype | |||||||||
Normalized | 132 | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | ||||
Not normalized | 85 | 1.48 (0.94 to 2.33) | .088 | 1.58 (1.02 to 2.43) | .039 | 1.26 (0.75 to 2.10) | .380 | 1.43 (0.70 to 3.12) | .360 |
Pre-HCT blood counts* | |||||||||
Recovered | 258 | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | ||||
Not recovered | 101 | 0.87 (0.59 to 1.29) | .490 | 0.86 (0.59 to 1.24) | .418 | 0.97 (0.61 to 1.57) | .910 | 1.08 (0.58 to 2.03) | .800 |
NOTE. No. of events: overall mortality, n = 168 deaths; failure for PFS, n = 189 events; relapse, n = 132 relapses/disease progressions; NRM, n = 57 deaths without prior experience of relapse/disease progression.
Abbreviations: AML, acute myeloid leukemia; HCT, hematopoietic cell transplantation; HR, hazard ratio; MRD, minimal residual disease; neg, negative; NRM, nonrelapse mortality; PFS, progression-free survival; pos, positive.
Recovered: absolute neutrophil count ≥ 1,000/µL and platelets ≥ 100,000/µL; not recovered: absolute neutrophil count < 1,000/µL and/or platelets < 100,000/µL